Nucleophosmin (NPM1) Mutation Analysis, Varies
Nucleophosmin (NPM1) Mutation Analysis, Varies-994
Nucleophosmin (NPM1) Mutation Analysis, Varies
994
LAB994
MSO
NPM1
NPM1 MRD
Nucleophosmin Mutation Analysis
NPM1 MRD
Nucleophosmin Mutation Analysis
As a prognostic indicator in patients with newly diagnosed acute myelogenous leukemia with normal karyotype and no FLT3 variant and as a leukemia-specific marker of minimal residual disease
Whole blood
10 mL
8 mL
Immediatley following collection, mix sample by inverting 8 - 10 times to prevent clotting
Do not spin; Send specimen in original tube.
Lavender (EDTA), 4mL
or
Yellow ACD-B
Bone marrow
4 mL
Immediatley following collection, mix sample by inverting 8 - 10 times to prevent clotting
Do not spin; Send specimen in original tube.
Lavender (EDTA), 4 mL
Yellow ACD-B
Refrigerated (preferred) - 5 days
Ambeint - 72 hours
- Gross hemolysis
- Moderately to severely clotted
- Bone marrow biopsies
- Paraffin-embedded bone marrow clots
- Slides
- Paraffin shavings
Mayo Clinic Laboratories (NPM1Q); R-NX
Mo - Sa
10-14 days
RNA: Reverse-Transcription Quantitative PCR (RT-qPCR)
DNA: Polymerase Chain Reaction (PCR) with Fragment Analysis by Capillary Gel Electrophoresis
See report
This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.
81310
03/04/2024
03/05/2024
03/04/2024